NO995565D0 - Farmasöytiske formuleringer inneholdende vorikonazol - Google Patents

Farmasöytiske formuleringer inneholdende vorikonazol

Info

Publication number
NO995565D0
NO995565D0 NO995565A NO995565A NO995565D0 NO 995565 D0 NO995565 D0 NO 995565D0 NO 995565 A NO995565 A NO 995565A NO 995565 A NO995565 A NO 995565A NO 995565 D0 NO995565 D0 NO 995565D0
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
formulations containing
containing voriconazole
voriconazole
pharmaceutical
Prior art date
Application number
NO995565A
Other languages
English (en)
Other versions
NO995565L (no
NO313125B1 (no
Inventor
Valerie Denise Harding
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO995565(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO995565D0 publication Critical patent/NO995565D0/no
Publication of NO995565L publication Critical patent/NO995565L/no
Publication of NO313125B1 publication Critical patent/NO313125B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19995565A 1997-06-21 1999-11-12 Farmasöytiske formuleringer inneholdende vorikonazol NO313125B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations
PCT/EP1998/003477 WO1998058677A1 (en) 1997-06-21 1998-06-02 Pharmaceutical formulations containing voriconazole

Publications (3)

Publication Number Publication Date
NO995565D0 true NO995565D0 (no) 1999-11-12
NO995565L NO995565L (no) 1999-11-30
NO313125B1 NO313125B1 (no) 2002-08-19

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995565A NO313125B1 (no) 1997-06-21 1999-11-12 Farmasöytiske formuleringer inneholdende vorikonazol

Country Status (48)

Country Link
US (1) US6632803B1 (no)
EP (1) EP1001813B8 (no)
JP (2) JP2000513029A (no)
KR (1) KR100372988B1 (no)
CN (1) CN1125653C (no)
AP (1) AP912A (no)
AR (1) AR015900A1 (no)
AT (1) ATE238812T1 (no)
AU (1) AU724799B2 (no)
BG (1) BG64584B1 (no)
BR (1) BRPI9809468B8 (no)
CA (1) CA2295035C (no)
CO (1) CO4940450A1 (no)
CZ (1) CZ289570B6 (no)
DE (1) DE69814091T2 (no)
DK (1) DK1001813T3 (no)
DZ (1) DZ2523A1 (no)
EA (1) EA001924B1 (no)
EG (1) EG23910A (no)
ES (1) ES2195355T3 (no)
GB (1) GB9713149D0 (no)
HK (1) HK1027966A1 (no)
HR (1) HRP980341B1 (no)
HU (1) HU228338B1 (no)
ID (1) ID22939A (no)
IL (1) IL132918A (no)
IS (1) IS2004B (no)
MA (1) MA26508A1 (no)
ME (1) ME00907B (no)
MY (1) MY118151A (no)
NO (1) NO313125B1 (no)
NZ (1) NZ501066A (no)
OA (1) OA11232A (no)
PA (1) PA8453201A1 (no)
PE (1) PE84899A1 (no)
PL (1) PL191295B1 (no)
PT (1) PT1001813E (no)
RS (1) RS49633B (no)
SA (1) SA98190159B1 (no)
SI (1) SI1001813T1 (no)
SK (1) SK282946B6 (no)
TN (1) TNSN98090A1 (no)
TR (1) TR199903191T2 (no)
TW (1) TW406023B (no)
UA (1) UA57083C2 (no)
UY (1) UY25055A1 (no)
WO (1) WO1998058677A1 (no)
ZA (1) ZA985364B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
GEP20063996B (en) * 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
BRPI0416870A (pt) * 2003-12-08 2007-01-30 Univ Arizona composições anticáncer sinergìticas
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
EP2303265B1 (en) * 2008-06-06 2014-12-10 Glenmark Pharmaceuticals Limited Stable topical formulation comprising voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EP2796134B1 (en) 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
WO2011020605A1 (en) 2009-08-19 2011-02-24 Ratiopharm Gmbh Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
BR112012033077B8 (pt) 2010-06-29 2023-04-25 Merck Sharp & Dohme Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
EP2409699B1 (en) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
KR101731155B1 (ko) 2011-06-15 2017-04-27 신톤 비.브이. 안정화된 보리코나졸 조성물
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013109421A1 (en) * 2012-01-05 2013-07-25 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
WO2013169897A1 (en) 2012-05-08 2013-11-14 Onyx Therapeutics, Inc. Cylodextrin complexation methods for formulating peptide proteasome inhibitors
EP2846769A1 (en) 2012-05-11 2015-03-18 Cipla Limited Pharmaceutical composition
EP2943224B1 (en) 2013-01-11 2020-01-01 Xellia Pharmaceuticals ApS Voriconazole inclusion complexes
CA2904670A1 (en) 2013-03-14 2014-09-13 Fresenius Kabi Usa, Llc Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
EP3584245A4 (en) 2017-02-17 2020-08-26 Wuhan LL Science And Technology Development Co., Ltd. TRIAZOLE ANTIBACTERIAL DERIVATIVE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP1001813B1 (en) 2003-05-02
NZ501066A (en) 2001-01-26
AU724799B2 (en) 2000-09-28
HUP0003323A3 (en) 2002-01-28
PE84899A1 (es) 1999-09-17
PL191295B1 (pl) 2006-04-28
JP2000513029A (ja) 2000-10-03
IL132918A0 (en) 2001-03-19
HRP980341B1 (en) 2001-12-31
CN1125653C (zh) 2003-10-29
HRP980341A2 (en) 1999-02-28
PT1001813E (pt) 2003-07-31
BG103882A (en) 2000-07-31
CN1261287A (zh) 2000-07-26
AP9801268A0 (en) 1998-06-30
ZA985364B (en) 1999-12-20
JP5089004B2 (ja) 2012-12-05
CA2295035A1 (en) 1998-12-30
SK282946B6 (sk) 2003-01-09
HUP0003323A2 (hu) 2001-06-28
MA26508A1 (fr) 2004-12-20
KR20010014006A (ko) 2001-02-26
AP912A (en) 2001-12-08
DK1001813T3 (da) 2003-07-28
KR100372988B1 (ko) 2003-02-25
AR015900A1 (es) 2001-05-30
CA2295035C (en) 2005-04-19
MY118151A (en) 2004-09-30
YU68199A (sh) 2002-06-19
HU228338B1 (en) 2013-03-28
CO4940450A1 (es) 2000-07-24
TW406023B (en) 2000-09-21
BR9809468B1 (pt) 2013-11-12
EP1001813A1 (en) 2000-05-24
UY25055A1 (es) 2000-12-29
SI1001813T1 (en) 2004-02-29
TNSN98090A1 (fr) 2005-03-15
ATE238812T1 (de) 2003-05-15
GB9713149D0 (en) 1997-08-27
IS2004B (is) 2005-04-15
EA199900937A1 (ru) 2000-08-28
BRPI9809468B8 (pt) 2022-01-18
JP2002332234A (ja) 2002-11-22
BR9809468A (pt) 2000-06-20
DE69814091T2 (de) 2004-01-22
NO995565L (no) 1999-11-30
ID22939A (id) 1999-12-16
BG64584B1 (bg) 2005-08-31
HK1027966A1 (en) 2001-02-02
UA57083C2 (uk) 2003-06-16
RS49633B (sr) 2007-08-03
AU8110498A (en) 1999-01-04
IL132918A (en) 2001-09-13
NO313125B1 (no) 2002-08-19
EP1001813B8 (en) 2014-02-12
OA11232A (en) 2003-05-26
CZ409699A3 (cs) 2000-02-16
ME00907B (me) 2007-08-03
ES2195355T3 (es) 2003-12-01
PL337692A1 (en) 2000-08-28
IS5248A (is) 1999-11-15
DE69814091D1 (de) 2003-06-05
CZ289570B6 (cs) 2002-02-13
SK159399A3 (en) 2000-06-12
EA001924B1 (ru) 2001-10-22
WO1998058677A1 (en) 1998-12-30
TR199903191T2 (xx) 2000-09-21
EG23910A (en) 2007-12-30
SA98190159B1 (ar) 2005-12-21
US6632803B1 (en) 2003-10-14
DZ2523A1 (fr) 2003-02-01
PA8453201A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
NO992339L (no) Farmasöytiske formuleringer
ID24654A (id) Formulasi farmasi omeprazola
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ID16781A (id) Formulasi-formulasi farmasi
ATE295150T1 (de) Pharmazeutische zusammensetzungen
ITMI941169A0 (it) Formulazioni farmaceutiche
ID25857A (id) Komposisi farmasi
ID23531A (id) Komposisi farmasi
DK1237551T3 (da) Farmaceutiske formuleringer indeholdende zolmitriptan
BR1100755A (pt) composição farmacêutica
ID21180A (id) Senyawa-senyawa farmasi
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SE9502453D0 (sv) Drug formulations
SE9404467D0 (sv) Drug formulations

Legal Events

Date Code Title Description
MK1K Patent expired